UK's NICE has recommended abemaciclib for advanced breast cancer in draft guidance.

UK's NICE has published draft guidance recommending twice-daily oral abemaciclib [Verzenios; Eli Lilly] for adults with hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body. The positive recommendation also follows an improved patient access scheme from the company, and with the addition of further economic modelling data, abemaciclib can now be considered a cost-effective use of NHS resources. [Extracted from the article]